Lyndra Therapeutics (Watertown, Mass.) announced that it is developing an ultra-long-acting oral treatment for opioid use disorder.
On average, about 130 Americans die every day from an opioid overdose, according to the Centers for Disease Control and Prevention. Lyndra Therapeutics received a grant from the National Institutes of Health to help find new treatment strategies and formulations of existing medications to address the opioid epidemic.
The grant covers the development of a once-a-week oral dosage of buprenorphine, which is a medication-assisted treatment that has shown to have improved outcomes for patients with opioid use disorder.